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The androgen receptor antagonist, flutamide, is strongly associated with idiosyncratic drug-
induced liver injury (DILI). Following administration, flutamide undergoes extensive first-pass 
metabolism to its primary metabolite, 2-hydroxyflutamide. Flutamide is a known 
mitochondrial toxicant; however there has been limited investigation into the potential 
mitochondrial toxicity of 2-hydroxyflutamide and its contribution to flutamide-induced liver 
injury. In this study we have used the acute glucose or galactose-conditioning of HepG2 cells 
to compare the mitochondrial toxicity of flutamide, 2-hydroxyflutamide and the structurally-
related, non-hepatotoxic androgen receptor antagonist, bicalutamide. Compound–induced 
changes in mitochondrial oxygen consumption rate were assessed using Seahorse technology. 
Permeabilisation of cells and delivery of specific substrates and inhibitors of the various 
respiratory complexes provided more detailed information on the origin of mitochondrial 
perturbations. These analyses were supported by assessment of downstream impacts including 
changes in cellular NAD+/NADH ratio. Bicalutamide was not found to be a mitochondrial 
toxicant, yet flutamide and 2-hydroxyflutamide significantly reduced basal and maximal 
respiration. Both flutamide and 2-hydroxyflutamide significantly reduced respiratory complex 
I-linked respiration, though 2-hydroxyflutamide also significantly decreased complex II and 
V-linked respiration; liabilities not demonstrated by the parent compound. This study has 
identified for the first time, the additional mitochondrial liabilities of the major metabolite, 2-
hydroxyflutamide compared with its parent drug, flutamide. Given the rapid production of this 
metabolite upon administration of flutamide, but not bicalutamide, we propose that the 
additional mitochondrial toxicity of 2-hydroxyflutamide may fundamentally contribute to the 
idiosyncratic DILI seen in flutamide-treated, but not bicalutamide-treated patients.  
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Introduction 
Drug-induced liver injury (DILI) represents a significant burden to health organisations and is 
a major contributor to cases of drug attrition (Kia et al., 2013). Recent figures estimate 20 new 
cases of DILI per 100 000 persons of the general population, with idiosyncratic DILI 
accounting for  11 % of acute liver failure cases in the U.S.A (Leise et al., 2014;  Yuan and 
Kaplowitz, 2013). Idiosyncratic cases of DILI, characterised by differences in individual 
susceptibility and a complex dose-response relationship, make it difficult to identify 
compounds with DILI liabilities prior to marketing (Chalasani et al., 2014). 
There are multiple mechanisms associated with the onset of DILI, and pre-clinical 
investigations are insensitive to some of them, contributing to the overall poor prediction of 
DILI. Possible mechanisms amongst these are the generation of reactive metabolites and 
mitochondrial dysfunction (Boelsterli and Lim, 2007;  Russmann et al., 2009). The high 
exposure of the liver to in situ-generated reactive metabolites results in this organ being 
particularly susceptible (Srivastava et al., 2010). The ionising conditions of the mitochondria 
encourage the accumulation of cationic compounds in this organelle, and this, coupled with the 
critical role of mitochondria in ATP production and apoptosis culminates in the potential for 
critical cellular injury upon mitochondrial dysfunction (Begriche et al., 2011;  Pessayre et al., 
2010). 
Flutamide, an androgen receptor antagonist, was first marketed for the treatment of prostate 
cancer in 1989. Cases of idiosyncratic DILI were subsequently reported, with cases of 
hospitalisation or death in 0.03 % of flutamide-treated patients, primarily presenting with 
cholestatic hepatitis (Chu et al., 1998;  Wysowski and Fourcroy, 1996). As a result, in 1999 
the Food and Drug Administration (FDA) applied a black box warning regarding the risk of 
hepatic necrosis and cholestasis in flutamide-treated patients (Coe et al., 2007).  
 In vitro studies have shown the inhibition of mitochondrial respiratory complex I (NADH 
ubiquinone oxidoreductase) activity by flutamide (Coe, et al., 2007). However, upon 
administration, flutamide undergoes extensive first-pass metabolism, primarily by conversion 
to 2-hydroxyflutamide via cytochrome P450 1A2 (CYP1A2), followed by glucuronidation 
before excretion (Figure 1) (Coe, et al., 2007;  Shet et al., 1997). Following a single 250 mg 
dose of flutamide its maximum plasma concentration (Cmax) is 72.2 nM, yet the Cmax  of 2-
hydroxyflutamide is 4.4 µM (Schulz et al., 1988).  Despite the  longer half-life (9.6 hours vs 
7.8 hours) and higher Cmax  of 2-hydroxyflutamide compared to its parent compound, the 
potential mitochondrial toxicity of 2-hydroxyflutamide as a contributor to flutamide-induced 
liver injury has not been fully investigated (Kostrubsky et al., 2007).  We hypothesised that 
because patients are exposed to such a high concentration of the 2-hydroxyflutamide 
metabolite, that it may contribute significantly to the toxicity exhibited upon flutamide 
administration and possibly through a mitochondrial mechanism.  
Hepatoma-derived HepG2 cells are often used as a model system for the identification of 
compounds with hepatic liabilities in early compound development. In an aerobic, high-glucose 
environment, such as in normal cell culture, these cells use oxidative phosphorylation 
(OXPHOS) as their main source of ATP, however they have the ability to increase utilisation 
of aerobic glycolysis for ATP production if required; rendering them less susceptible to 
mitochondrial toxicants (Diaz-Ruiz et al., 2011;  Marroquin et al., 2007;  Rodríguez‐Enríquez 
et al., 2001). Replacing glucose in medium with galactose reduces the ATP yield from 
glycolysis, so  increases the reliance on OXPHOS for ATP production in HepG2 cells; 
providing increased sensitivity to mitochondrial toxicants than in glucose-conditioned cells 
(Kamalian et al., 2015;  Marroquin, et al., 2007).  
This study aimed to compare the mitochondrial toxicity induced by 2-hydroxyflutamide to that 
induced by flutamide, initially by comparing measurements of cytotoxicity and cellular ATP 
content in glucose-conditioned HepG2 cells with the same endpoints in HepG2 cells subject to 
acute galactose-conditioning. Bicalutamide, a non-mitotoxic structural counterpart of 
flutamide which is not associated with idiosyncratic DILI was also tested as a negative control 
(Figure 1). Subsequently, oxygen consumption rate (OCR) assessment and HepG2 cell 
permeabilisation were used for in-depth analysis of mitochondrial dysfunction, followed by 
assessment of the downstream impact of perturbations induced by the parent compound and 
metabolite.  
It was demonstrated for the first time, to the best of our knowledge, that 2-hydroxyflutamide, 
like flutamide, is an inhibitor of respiratory complex I in HepG2 cells. In addition, 2-
hydroxyflutamide was found to be an inhibitor of respiratory complexes II (succinate 
dehydrogenase) and V (ATP synthase) activity, perturbations not induced by the parent 
compound. This study has highlighted the importance of the toxicological analysis of major 
chemical metabolites and identifies 2-hydroxyflutamide as a potential significant contributor 
to flutamide-induced liver injury. These findings are not only relevant to the development of 
future androgen receptor antagonists but to all therapeutics in which hepatic dysfunction 
potentially due to mitochondrial dysfunction is evident. 
Figure 1 Flutamide, 2-hydroxyflutamide and bicalutamide chemical structures. Flutamide is rapidly 
hydroxylated (A) to 2-hydroxyflutamide upon administration. This primary metabolite has been shown to have 
higher androgen receptor binding affinity than its parent compound (Shet, et al., 1997). Bicalutamide was derived 
from flutamide by the addition of a 4-fluorophenylsulfonyl moiety (B) and also notably replaces the nitroaromatic 
structural alert in flutamide with a cyano group (C).  
Materials and Methods 
Materials 
All forms of DMEM, mitoSOX red indicator and rat tail collagen I were purchased from Life 
Technologies (Paisley, UK). HepG2 cells were purchased from European Collection of Cell 
Cultures (ECACC, Salisbury, UK). NAD+/NADH ratio assay kit was purchased from eEnzyme 
(MD, USA). Cytotoxicity detection kits were purchased from Roche Diagnostics Ltd (West 
Sussex, UK). Clear and white 96-well plates were purchased from Fisher Scientific 
(Loughborough, UK) and Greiner Bio-One (Stonehouse, UK) respectively. All OCR 
consumables were purchased from Seahorse Bioscience (North Billerica, MA, USA). All other 
reagents and chemicals were purchased from Sigma Aldrich (Dorset, UK). 
 
Cell culture 
HepG2 cells were maintained in DMEM high-glucose medium (glucose; 25 mM) 
supplemented with FBS (10 % v/v), L-glutamine (2 mM), sodium pyruvate (1 mM) and HEPES 
(1 mM).  All cells were incubated at 37 °C and 5 % CO2. Cells were used up to passage 20. 
 
Cell plating and metabolic switch 
Metabolic switching of cells was performed based on work previously described by (Kamalian, 
et al., 2015). Briefly, 24 hours prior to metabolic switch, HepG2 cells were collected by 
trypsinisation and seeded on a collagen-coated flat-bottomed 96-well plate (20 000 cells/50 
µL/well) and incubated (37 °C, 5 % CO2) overnight. On the morning of the experiment, cells 
were washed three times in either glucose or galactose medium (DMEM containing 25 mM 
glucose and 4 mM L-glutamine or 10 mM galactose and 6 mM L-glutamine respectively (extra 
L-glutamine was provided to ensure this was not a limiting factor upon increased OXPHOS 
reliance), plus supplements listed in cell culture, only dialysed FBS (to remove trace amounts 
of glucose) was used in galactose medium before incubation (2 h, 37 °C, 5 % CO2). Flutamide, 
2-hydroxyflutamide and bicalutamide stock solutions were prepared in DMSO and diluted 
further in the appropriate medium. Compounds (50 µL) were then added to each well and cells 
were incubated for 2 h (37 °C, 5 % CO2). All assays used ≤ 0.5 % DMSO as a vehicle control.   
 
Dual assessment of mitochondrial function (ATP content) alongside cytotoxicity (LDH 
release) 
Following compound incubation (0.05 – 300 µM flutamide, 2-hydroxyflutamide or 
bicalutamide) with cells in glucose or galactose medium (2 h), cell supernatant was extracted 
and the cells lysed using somatic cell ATP releasing agent. LDH content of the cells and 
supernatant was assessed using a cytotoxicity detection kit according to the manufacturer’s 
instructions.  ATP content was assessed using an ATP bioluminescent assay according to the 
manufacturer’s instructions. Briefly, 10 µL of cell lysate and ATP standard curve solutions 
were added to a white-walled 96-well plate before addition of 40 µL ATP assay mix. Protein 
content of all wells was then assessed using a BCA assay applied to 10 µL of cell lysate and 
standards.  LDH (490 nm), BCA (570 nm) and ATP assay luminescence were then measured 
using a plate reader (Varioskan, Thermo Scientific). ATP content readings were normalised to 
protein content.  
 
 
OCR analysis  
Assay preparation 
HepG2 cells were collected by trypsinisation and seeded on a collagen-coated XF 96-well cell 
culture microplate (25 000 cells/100 µL medium/well) and incubated (37 °C, 5 % CO2) 
overnight. All assays used ≤ 0.5% DMSO as a vehicle control.   
Mitochondrial stress test 
Cells were  incubated for 1 h (37 °C, 0 % CO2) before culture medium was replaced by 175 µL 
of unbuffered Seahorse XF Base medium supplemented with glucose (25 mM), L-glutamine 
(2 mM), sodium pyruvate (1 mM), pre-warmed to 37 °C (pH 7.4). Prior to measurement of 
OCR, the Seahorse XFe96 instrument gently mixed the assay medium in each well for 10 min 
to enable the oxygen partial pressure to reach equilibrium. The OCR was then measured three 
times to establish a baseline rate prior to the acute injection of flutamide, 2-hydroxyflutamide 
or bicalutamide (7.8-500 µM). There were nine OCR measurement cycles following compound 
injection and each measurement cycle consisted of a 3 min mix and 3 min measure. Following 
this compound incubation (54 min), a mitochondrial stress test was performed consisting of 
sequential injections of oligomycin (1 µM), carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone (FCCP) (0.5 µM) and antimycin A/rotenone (1 µM each) (all compound 
concentrations were optimised to generate the maximum effect in the absence of toxicity). 
After stress test compound injections there were three measurement cycles before the injection 
of the next stress test compound. This enabled the calculation of basal respiration (OCR prior 
to oligomycin injection – non-mitochondrial OCR), proton leak (OCR after oligomycin 
injection – non mitochondrial OCR), ATP-linked OCR (basal respiration – proton leak – non-
mitochondrial OCR), maximal respiration (first injection after FCCP injection – non-
mitochondrial OCR) and spare respiratory capacity (maximal respiration – basal respiration) 
(Figure 2).  
Figure 2 Representative control mitochondrial stress test trace. Mitochondrial stress test assays consisted of 
a series of compound injections into the cell culture microplate. Flutamide/2-hydroxyflutamide or vehicle control 
(shown) was first injected, followed by nine measurement cycles.  Remaining injections consisted of oligomycin 
(ATP synthase inhibitor), FCCP (OXPHOS uncoupler) and rotenone/antimycin A (complex I and III inhibitors 
respectively) with each followed by three measurement cycles. This series of manipulations enabled the 
calculation of parameters: basal, ATP-linked, maximum and non-mitochondrial OCR, as well as proton leak. Each 
measurement cycle was a total of 6 min. 
In situ respiratory complex assay in permeabilised cells 
Culture medium was replaced with mitochondrial assay solution buffer (MAS) (MgCl2; 5 mM, 
mannitol; 220 mM, sucrose; 70 mM, KH2PO4; 10 mM, HEPES; 2 mM, EGTA; 1 mM; BSA; 
0.4 % w/v) and plasma membrane permeabiliser (PMP) (1 nM) containing constituents to 
uncouple cells and stimulate oxygen consumption via complex I (ADP; 4.6 mM, malic acid; 
30 mM, glutamic acid; 22 mM, BSA; 30 µM, PMP; 1 nM, FCCP; 8 µM) (All compound 
concentrations were optimised to generate the maximum effect in the absence of toxicity)  and 
flutamide or 2-hydroxyflutamide (10-250 µM). PMP is a recombinant form of perfringolysin 
O, a cholesterol-specific pore-forming reagent which requires a higher threshold level of 
cholesterol than native perfringolysin O. This enables selective permeabilisation of the cell 
membrane whilst having little or no effect on cholesterol-deficient mitochondrial membranes 
(Divakaruni et al., 2013;  Salabei et al., 2014). Permeabilisation of the cell membrane not only 
permitted mitochondrial access to all of the substrates and inhibitors used, but also depleted 
the cells of all cytosolic stores, ensuring that mitochondrial electron transport could be 
specifically driven by the substrates provided. The use of FCCP-treated (uncoupled) cells 
ensured that any deviations seen were due to perturbations at specific respiratory complexes 
and not due to inefficiencies in the coupling of OXPHOS. 
Following a basal measurement of three cycles of mix (30 s), wait (30 s) and measure (2 min), 
sequential injections of A: rotenone (2 µM), B: succinate + rotenone (20 mM, 2 µM 
respectively), C: antimycin A (2 µM) and D: ascorbic acid + N,N,N′,N′-tetramethyl-p-
phenylenediamine (TMPD) + antimycin A (20 mM, 0.5 mM and 2 µM respectively) were 
performed with a two cycle interval between each, allowing measurement of changes in 
complexes I (A), II (B) and IV (C and D) activity respectively (Figure 3). MAS buffer, all 
constituents and compound injections were used at pH 7.2.  
Figure 3 Representative in situ respiratory complex assay trace. In situ respiratory complex assays consisted 
of cells in a solution containing substrates for complex I and flutamide/2-hydroxyflutamide or vehicle control 
(shown) prior to three cycles of measurements and a series of compound injections into the cell culture microplate. 
Injections consisted of rotenone (complex I inhibitor), succinate (complex II substrate), antimycin A (complex III 
inhibitor) and TMPD/ascorbate (complex IV substrates) with two cycles of measurements following each. This 
series of manipulations enabled the calculation of complex I (A), II (B) and IV (C) activity. Each measurement 
cycle was a total of 3 min. 
Complex I, II and III-linked respiration assays in permeabilised cells 
Culture medium was replaced with MAS buffer containing constituents to stimulate oxygen 
consumption via complex I (as previously without FCCP),  complex II (ADP; 4.6 mM, 
succinate; 20 mM, rotenone; 1 µM, BSA; 0.2 % w/v, PMP; 1 nM) or complex III (ADP; 4.6 
mM, duroquinol; 500 μM, rotenone; 1 μM, malonic acid; 40 μM, BSA; 0.2 % w/v, PMP; 1 
nM) dependent on the respiratory complex of interest. Following a basal OCR measurement of 
three cycles of mix (30 s), wait (30 s) and measure (2 min), flutamide/2-hydroxyflutamide were 
injected (10-250 µM) and three cycles of measurement made again, prior to a mitochondrial 
stress test as detailed previously but with changes to stress test compound concentrations; 
oligomycin (1 μM), FCCP (10 μM), rotenone/antimycin A (2 μM). Changes in complex II 
activity were also assessed at lower compound concentrations; 2-30 μM (Supplementary Figure 
1). Complex I, II and III activity were defined by the change in complex I, II or III-stimulated 
maximal respiration respectively compared to vehicle control.  
Complex V assay in permeabilised cells 
Culture medium was replaced with MAS buffer containing constituents to stimulate oxygen 
consumption via complex IV as this was not significantly affected by either compound  in the 
in situ respiratory complex assay (ADP; 4.6 mM, ascorbic acid; 20 mM, TMPD; 0.5 mM, 
antimycin A; 2 µM, BSA; 30 µM, PMP; 1 nM). The assay consisted of a basal OCR 
measurement of two cycles of mix (30 s), wait (30 s) and measure (2 min) followed by MAS 
or FCCP injection (0.5 µM) and two measurement cycles. MAS-injected cells remain coupled 
whereas FCCP-injected cells become uncoupled meaning Complex V (ATP synthase) 
inhibition should not result in a change in OCR.  Either flutamide, 2-hydroxyflutamide (10-
250 µM) or oligomycin (positive control; 1 µM) was then injected into both the uncoupled and 
coupled cells, followed by a final two measurement cycles (Figure 4). Change in complex V 
activity was defined as the difference in flutamide/2-hydroxyflutamide-induced OCR change 
between coupled (MAS injection) and uncoupled (FCCP injection) cells compared to vehicle 
control.  
Figure 4 Representative complex V assay trace. Complex V assays consisted of cells in a solution containing 
substrates for complex IV before a series of compound injections into the cell culture microplate. FCCP (OXPHOS 
uncoupler) (Trace A) or MAS buffer (Traces B and C) was first injected, followed by two cycles of measurements. 
Flutamide, 2-hydroxyflutamide, oligomycin (positive control) or vehicle control was then injected into both the 
uncoupled (FCCP-treated) and coupled (MAS-treated) cells. Change in complex V activity was defined as the 
reduction in OCR of coupled cells upon flutamide/2-hydroxyflutamide injection minus the change in OCR of 
uncoupled cells, as a % of vehicle control. Injections for traces shown; A: FCCP, 250 μM 2-hydroxyflutamide, 
B: MAS, 250 μM 2-hydroxyflutamide, C: MAS, Oligomycin. Each measurement cycle was a total of 3 min. 
Normalisation of OCR assays to protein content 
Following completion of OCR assays, medium was removed from all wells and 20 µL of 
somatic cell ATP releasing agent was added to each well before shaking for 1 minute and 
transfer of 10 µL of lysate to a 96-well plate and performance of a BCA assay according to the 
manufacturer’s instructions. Protein content per well was used to normalise OCR. 
Assessment of superoxide production 
HepG2 cells were collected by trypsinisation and seeded on a 24-well plate (150 000 cells/500 
µL/well) and incubated overnight in glucose medium (37 °C, 5 % CO2). Cells were then treated 
with fresh glucose medium containing 15-500 µM flutamide or 2-hydroxyflutamide and 
incubated for 2 h (37 °C, 5 % CO2). mitoSOX red indicator was then added to each well (5 
µL/well)  and cells were incubated in the dark for 30 min (37 °C, 5 % CO2) before collection 
of cells by trypsinisation and absorbance measured at 396/579 nm in a white-walled 96-well 
plate. Protein content per well was determined using a BCA assay (as described above) and 
was used to normalise superoxide levels. 
Assessment of NAD+/NADH ratio 
HepG2 cells were collected by trypsinisation and seeded on a 24-well plate (450 000 cells/500 
µL/well) and incubated overnight in glucose medium (37 °C, 5 % CO2). Cells were then treated 
with fresh glucose medium containing 30-500 µM flutamide or 2-hydroxyflutamide and 
incubated for 2 h (37 °C, 5 % CO2). NAD
+ and NADH concentrations were measured in lysates 
using a NAD+/NADH ratio assay kit according to the manufacturer’s instructions. 
Data and statistical analysis 
Experiments were conducted in a minimum of triplicate to ensure the reliability of single 
values. EC50 data were determined by nonlinear regression analysis using GraphPad Prism 5.0. 
Normality was assessed using a Shapiro-Wilk statistical test. Statistical significance was 
determined by an unpaired t-test for parametric data and a Mann-Whitney U test for non-
parametric data using StatsDirect 2.7.9. P < 0.05 was taken as showing a significant difference. 
 Results 
Flutamide and 2-hydroxyflutamide decrease cellular ATP content significantly more in 
galactose medium than glucose medium  
When the concentration of a compound required to reduce cellular ATP content by 50 % 
(EC50ATP) is compared in glucose-conditioned vs galactose-conditioned cells, a fold 
difference of  ≥ 2 (EC50ATPglu/EC50ATPgal ≥ 2)  is considered to indicate that the compound 
contains a  mitochondrial liability  (Kamalian, et al., 2015;  Swiss et al., 2013). None of the 
compounds induced significant cytotoxicity in HepG2 cells (quantified in this study as a 
significant increase in LDH release) in either glucose or galactose medium. However, the 
decrease in ATP content induced by flutamide and 2-hydroxyflutamide was significantly more 
in the galactose medium, but this was not the case for bicalutamide (Figures 5 A, B, C).  This 
translated into an EC50ATP ratio (glucose vs galactose media) ≥ 2 for flutamide and 2-
hydroxyflutamide, whereas the difference in EC50 induced by bicalutamide was ≤ 2 and was 
not significant (Table 1).  
Figure 5 The effect of flutamide (A), 2-hydroxyflutamide (B) and bicalutamide (C) exposure on ATP 
content and cytotoxicity of HepG2 cells (2 h) compared to vehicle control. Serial concentrations of compounds 
were used up to 300 µM in glucose or galactose media. ATP values are expressed as a percentage of those of the 
vehicle control, LDH release is expressed as extracellular LDH as a % of total LDH. Statistical significance 
compared to vehicle control; glucose *P<0.05;**P<0.01;***P<0.001, galactose +P<0.05; ++P<0.01; +++P<0.001, 
between glucose and galactose ^P<0.05; ^^P<0.01; ^^^P<0.001. All results were normalised to µg protein per 
well. Data are presented as mean ± SEM of n=3 experiments. 
 
  
EC50ATP refers to the concentration of the compound required to reduce cellular ATP content by 50 %. 
Comparison of this value in cells treated in glucose or galactose medium identifies a mitochondrial liability if 
EC50ATPglu/EC50ATPgal ≥ 2. P value indicates the significance of EC50ATPglu compared to EC50ATPgal.  
Flutamide and 2-hydroxyflutamide decrease mitochondrial spare respiratory capacity 
and ATP-linked OCR and increase proton leak 
Following the identification of mitochondrial liabilities in flutamide and 2-hydroxyflutamide, 
the effect of these compounds on mitochondrial OCR was assessed using a mitochondrial stress 
test (Figure 2). Both flutamide and 2-hydroxyflutamide induced a significant decrease in basal 
and maximal respiration whereas bicalutamide only caused a significant decrease in maximal 
respiration (Figures 6A, B). Both flutamide and 2-hydroxyflutamide (Figures 6C, D) also 
caused a significant increase in proton leak and a significant decrease in spare respiratory 
capacity and ATP-linked OCR as a percentage of maximal respiration, changes which were 








EC50ATPglu/ EC50ATPgal (p value) 
Glucose Galactose 
Flutamide 255 43.9 5.82 (0.03) 
2-hydroxyflutamide 267 48.5 5.51 (0.01) 
Bicalutamide 148 103 1.44 (0.22) 
Table 1 Comparison of the effect of flutamide, 2-hydroxyflutamide and bicalutamide exposure on 
intracellular ATP content of HepG2 cells (2 h) in glucose and galactose medium 
Figure 6 The effect of flutamide, 2-hydroxyflutamide and bicalutamide on mitochondrial OCR in HepG2 
cells. Serial concentrations of compounds were used up to 500 µM. (A) and (B) Changes in basal and maximal 
respiration respectively. Changes in proton leak, spare respiratory capacity and ATP-linked OCR induced by 
flutamide (C) 2-hydroxyflutamide (D) and bicalutamide (E).  Statistical significance compared to vehicle control; 
(A) and (B) flutamide;*P<0.05;**P<0.01;***P<0.001, 2-hydroxyflutamide; +P<0.05; ++P<0.01;+++P<0.001, and 
bicalutamide; ^P<0.05; ^^P<0.01;^^^P<0.001. (C), (D) and (E) *P<0.05;**P<0.01;***P<0.001. All results were 
normalised to µg protein per well. Data are presented as mean ± SEM of n=3 experiments. 
2-hydroxyflutamide but not flutamide induces a significant reduction in complex II 
activity 
Given the significant change in mitochondrial OCR induced by flutamide and 2-
hydroxyflutamide, the effects of the compounds on the mitochondrial respiratory chain 
complexes were examined using an in situ respiratory complex assay in permeabilised HepG2 
cells (Figure 3). Both flutamide and 2-hydroxyflutamide-treated cells responded significantly 
less to complex I inhibition by rotenone compared to control, implying a significant reduction 
in complex I activity following treatment with either compound (Figure 7A). Only 2-
hydroxyflutamide induced a significantly reduced response to complex II stimulation by 
succinate, implying compromised complex II activity (Figure 7B). Neither compound appeared 
to have a significant impact upon complex IV (Figure 7C). 
 
Figure 7 The effect of flutamide and 2-hydroxyflutamide exposure on the activity of mitochondrial 
respiratory complexes I (A), II (B) and IV (C) in uncoupled, permeabilised HepG2 cells. Compounds were 
used at 10-250 µM. Statistical significance compared to vehicle control; *P<0.05;**P<0.01;***P<0.001. All 
results were normalised to µg protein per well. Calculation of changes in complex activity is described in Figure 





2-hydroxyflutamide has additional mitochondrial liabilities compared to its parent 
compound  
Identification of a significant reduction in complex I and II activity following flutamide/2-
hydroxyflutamide treatment prompted the specific investigation of compound-induced changes 
in maximal respiration driven by these complexes. Cells were permeabilised in a solution 
containing substrates specific for the complex of interest before being treated with flutamide 
or 2-hydroxyflutamide and a mitochondrial stress test. A significant reduction in complex I 
activity was induced by both compounds at 30 µM and above (Figure 8A). In agreement with 
in situ respiratory complex assay results, only 2-hydroxyflutamide and not flutamide induced 
a significant reduction in complex II activity (Figure 8B). Assessment of complex V activity 
by comparison of compound-induced OCR change in uncoupled and coupled cells showed a 
significant reduction in complex V activity following treatment with 2-hydroxyflutamide at 
125 µM and above, though this was not the case for flutamide (Figure 8D). Assessment of 










Figure 8 The effect of flutamide and 2-hydroxyflutamide exposure on the activity of mitochondrial 
respiratory complexes I (A), II (B), III (C) and V (D) in permeabilised HepG2 cells. Compounds were used 
at 10-250 µM. Statistical significance compared to vehicle control; *P<0.05;**P<0.01;***P<0.001. Complex I, 
II and III activity were defined as complex I, II or III-stimulated maximal respiration respectively, compared to 
vehicle control. Complex V activity was defined as the difference in compound-induced OCR change between 
coupled and uncoupled cells relative to vehicle control. All results were normalised to µg protein per well. Data 
are presented as mean + SEM of n=3 experiments.  
 
Flutamide and 2-hydroxyflutamide increase superoxide generation and reduce the 
intracellular ratio of NAD+/NADH 
Downstream impacts of mitochondrial dysfunction, particularly complex I inhibition, include 
increased generation of reactive oxygen species and depletion of cellular NAD+. Both 
flutamide and 2-hydroxyflutamide significantly increased cellular superoxide at 30 µM and 
above, the same concentration at which significant reductions in complex I-mediated maximal 
respiration were observed (Figures 8A, 9A). A significant increase in superoxide was also seen 
in galactose media at the same compound concentrations (Supplementary Figure 2). Both 
compounds also significantly decreased the NAD+/NADH ratio (Figure 9B), though not at 
concentrations below 100 µM.  
Figure 9 The effect of flutamide and 2-hydroxyflutamide exposure on superoxide levels (A) and 
NAD+/NADH ratio (B) in HepG2 cells (2h). Serial concentrations of compounds were used up to 500 µM. 
Statistical significance compared to vehicle control; flutamide; *P<0.05;**P<0.01;***P<0.001, 2-
hydroxyflutamide; +P<0.05;+P<0.01;+++P<0.001.  mitoSOX results were normalised to µg protein per well. Data 
are presented as mean ± SEM of n=3 experiments. 
Data available from the Dryad Digital Repository (Ball et al., 
2016): http://dx.doi.org/10.5061/dryad.jj456 
Discussion 
The use of the anti-androgen, flutamide is restricted due to its associated idiosyncratic 
hepatotoxicity. The rapid first-pass metabolism of flutamide, primarily by CYP1A2 to 2-
hydroxyflutamide, results in the parent drug only comprising 2.5 % of detectable compound in 
the plasma following administration (Radwanski et al., 1989). Flutamide is a known inhibitor 
of mitochondrial respiratory complex I but despite the generation of significant amounts of 2-
hydroxyflutamide, the potential mitochondrial liability of this metabolite has not yet been fully 
examined, prompting its investigation in this study (Coe, et al., 2007).   
The ability of HepG2 cells in glucose medium to increase glycolysis upon mitochondrial 
perturbation(s) reduces the ability to identify mitochondrial toxicants and their impact upon 
cellular ATP content (Crabtree, 1929;  Diaz-Ruiz, et al., 2011). However, when glucose 
medium is switched to galactose medium, the net yield of ATP from glycolysis is significantly 
reduced, increasing the reliance of HepG2 cells upon OXPHOS and mitochondrial toxicity is 
more evident (Reitzer et al., 1979). This was demonstrated by the significantly greater decrease 
in cellular ATP content following flutamide or 2-hydroxyflutamide treatment of acutely 
galactose-conditioned cells vs glucose-cultured cells (Figures 5A, B). An 
EC50ATPglu/EC50ATPgal ≥ 2 indicates a mitochondrial liability; a threshold surpassed by 
flutamide and 2-hydroxyflutamide in the absence of a significant increase in cytotoxicity, 
suggesting mitochondrial liabilities in both the parent compound and metabolite (Table 1).  
The potential for 2-hydroxyflutamide generation in flutamide-treated HepG2 cells must be 
acknowledged, though the absence of detectable CYP1A2 activity in HepG2 cells and 40-fold 
lower expression than in primary human hepatocytes, together with the immediate reduction in 
OCR following flutamide injection during mitochondrial stress tests and complex I respiratory 
analyses (Supplementary Figure 3) has provided relative confidence that the effect of 2-
hydroxyflutamide in flutamide-treated cells would have been negligible during the study 
(Ranade et al., 2014;  Sison-Young et al., 2015).  
Given that flutamide has a black box warning for hepatotoxicity, bicalutamide has become one 
of the front-line treatments for androgen-sensitive prostate cancer. Cells treated with 
bicalutamide in galactose medium did not have significantly reduced ATP content compared 
to glucose-conditioned cells, indicating that bicalutamide has no direct mitochondrial liability 
in HepG2 cells at the concentrations used (Figure 5C).  
More detailed analysis of mitochondrial function using OCR analysis and assessment of 
downstream impacts of mitochondrial perturbations was only performed in glucose media, as 
in this environment  HepG2 cells primarily use OXPHOS for ATP production, meaning that 
mitochondrial perturbations were still evident whilst  deviating less from standard cell culture 
conditions than with galactose medium (Diaz-Ruiz, et al., 2011). OCR analysis using a 
mitochondrial stress test (Figure 2) demonstrated a significant increase in proton leak and 
decrease in ATP-linked OCR upon flutamide or 2-hydroxyflutamide treatment (Figures 6C, 
D), indicative of a loss of electron transport chain function and/or uncoupling of OXPHOS. 
The spare respiratory capacity of cells also significantly decreased upon treatment with 
flutamide or 2-hydroxyflutamide, representative of an inability of cells to increase OCR upon 
treatment with the uncoupler, FCCP (Figures 6C, D). All changes in these parameters were 
considered relative to maximal respiration, although at high concentrations (500 µM flutamide 
or 2-hydroxyflutamide) this method was not reliable as the post-FCCP readings suggested that 
the cells were already uncoupled and resistant to any further dissipation of the proton gradient. 
These changes were not seen upon bicalutamide treatment at the same concentrations (Figure 
6E), with the mitochondria still able to further increase OCR upon FCCP treatment, an adaptive 
ability which was severely compromised by flutamide or 2-hydroxyflutamide treatment. The 
fact that bicalutamide did not erode spare respiratory capacity as flutamide or 2-
hydroxyflutamide did may contribute to the absence of hepatotoxicity in bicalutamide-treated 
patients, despite the higher Cmax  and longer half-life (1.7 µM and 6 days respectively from a 
single 50 mg dose) of the active (R)-bicalutamide compared to flutamide (Cockshott, 2004).   
To further investigate the mitochondrial target of these compounds, an in situ respiratory 
complex assay was used to identify dysfunction in respiratory complexes I, II and IV using 
permeabilised cells generated by a cholesterol-specific agent (PMP) (Figure 3). The use of 
OCR analysis in permeabilised cells as oppose to traditional methods using isolated 
mitochondria has allowed circumvention of the limitations of mitochondrial isolation, 
including bias from sub-selection of the mitochondrial population during isolation and limited 
quality control (Kuznetsov et al., 2008). Neither flutamide nor 2-hydroxyflutamide 
significantly changed complex IV activity (Figure 7C), prompting individual analysis of only 
complexes I, II (significant change in activity during in situ respiratory complex assays) and 
III (activity not determined during in situ respiratory complex assays) activity. This identified 
an absence of complex III inhibition by either compound (Figure 8C) but identified both the 
parent compound and metabolite as inhibitors of complex I activity, though the effect was 
greater with 2-hydroxyflutamide (Figure 8A). As expected from the in situ respiratory complex 
assay results, only 2-hydroxyflutamide induced a significant decline in complex II activity at 
10 μM and above (Figure 8B) (Supplementary Figure 1). This dual inhibition of complex I and 
II activity by 2-hydroxyflutamide is likely to result in a more severe impact on OXPHOS, as 
electrons donated by both NADH and FADH2 are unable to be accepted. Conversely, if only 
complex I is inhibited, as in the case of flutamide, then electron entry is still possible 
downstream via complex II, implying a greater risk associated with 2-hydroxyflutamide.  In 
addition to dual complex I and II liabilities, treatment with 2-hydroxyflutamide also induced a 
significant decrease in ATP synthase activity at higher concentrations (Figure 8D).  
The reduced ratio of NAD+/NADH in flutamide and 2-hydroxyflutamide-treated cells was 
consistent with complex I inhibition by both parent compound and metabolite and suggests the 
failure of complex I to oxidise NADH (Figure 9B).  Imbalances in this ratio have been shown 
to inhibit NAD+-dependent enzymes, particularly sirtuin 3, leading to hyperacetylation of target 
protein lysine residues and dysregulation of mitochondrial homeostasis (Lombard et al., 2007). 
The significant increase in superoxide level upon flutamide and 2-hydroxyflutamide exposure 
occurred at a lower concentration than the significant increase in proton leak (indicative of 
OXPHOS uncoupling), implying that increased superoxide production can also be attributed 
to the reduction in complex I activity exhibited in the same concentration range (Figure 9A).  
Whilst the low metabolic capacity of HepG2 cells enabled the study of the parent compound 
and the selected metabolite separately in this study, the use of a cell line with low metabolism 
has been limiting in that it has prevented analysis of a wider spectrum of potential metabolites 
that may be derived from the parent compound and could contribute to the overall toxicity.  
Specifically, 2-hydroxyflutamide (Cmax;  4.4 µM) is the primary metabolite of flutamide, but 
other minor metabolites are formed, though in much lower abundance, including the hydrolysis 
product, 3-trifluoromethyl-4-nitroaniline (Cmax;  1.31 µM) (Schulz, et al., 1988). Another factor 
which should be considered is the action of flutamide and 2-hydroxyflutamide as inhibitors of 
taurocholate efflux (IC50 75 µM and 110 µM respectively) via bile salt export pump inhibition 
(Kostrubsky, et al., 2007). Importantly, the 16-fold reduction in expression of this efflux pump 
in HepG2 cells may have been advantageous as it has allowed direct inhibition of mitochondrial 
respiratory complexes to be identified in a situation of low active bile-salt export (Sison-
Young, et al., 2015). This study has therefore indicated that a significant proportion of 
mitochondrial toxicity could be occurring independently of bile salt-mitochondrial interaction, 
but the concentrations at which flutamide and 2-hydroxyflutamide have been found to 
significantly inhibit taurocholate efflux do overlap with concentrations which significantly 
inhibit respiratory complex activity, providing scope for a synergistic effect (Aleo et al., 2014).  
In conclusion, the rapid generation of 2-hydroxyflutamide in vivo, alongside the perturbation 
of multiple respiratory complexes in HepG2 cells raises the possibility that hepatotoxicity 
induced by flutamide may be due, at least in part, to the additional mitochondrial liabilities of 
2-hydroxyflutamide, the basis of which requires detailed chemical modelling. The generation 
of this mitotoxic metabolite further differentiates flutamide from bicalutamide in terms of its 
hepatotoxic potential. The concentrations used in this study do greatly exceed the maximum 
concentrations of flutamide and 2-hydroxyflutamide seen in patient plasma, however 
identification of direct mitochondrial targets of this compound and its metabolite in the absence 
of bile salt-mediated toxicity has provided a mechanistic starting point for evaluation of 
interindividual differences in susceptibility to flutamide-induced liver injury. Given the nature 
of the additional mitochondrial liabilities of 2-hydroxyflutamide, pre-existing functional 
differences in the basal activity of complexes I, II and V and differential rates of 2-
hydroxyflutamide glucuronidation in individuals now form areas of particular interest in the 
effort to identify susceptible individuals and stratify patients for treatment accordingly. 
 
Supplementary data description 
Supplementary Figure 1 shows the assessment of the effect of 2-hydroxyflutamide on complex 
II activity at lower concentrations than shown in the main text. Supplementary Figure 2 shows 
superoxide levels upon flutamide/2-hydroxyflutamide treatment in galactose-conditioned 
HepG2 cells. Supplementary Figure 3 displays OCR traces showing the immediate reduction 
in OCR induced by flutamide in mitochondrial stress tests and complex I assays.  
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